

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : A61K 31/47, 31/165, 31/11, 31/12, 35/78, 7/26, 7/16		A1	(11) International Publication Number: WO 98/44926 (43) International Publication Date: 15 October 1998 (15.10.98)
(21) International Application Number: PCT/US98/06468 (22) International Filing Date: 1 April 1998 (01.04.98)		(74) Agent: SAKOI, Jeffrey, M.; Christensen O'Connor Johnson & Kindness, Suite 2800, 1420 Fifth Avenue, Seattle, WA 98101 (US).	
(30) Priority Data: 08/832,821 4 April 1997 (04.04.97) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/832,821 (CON) Filed on 4 April 1997 (04.04.97)		Published <i>With international search report.</i>	
(71) Applicant (for all designated States except US): OPTIVA CORP. [US/US]; 13222 Southeast 30th Street, Bellevue, WA 98005 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): IYER, Lokanathan, M. [US/US]; 14718 60th Avenue West, Edmonds, WA 98026 (US). SCOTT, James, R. [US/US]; 5805 228th Street Southeast, Bothell, WA 98021 (US). WHITFIELD, Douglas, F. [US/US]; 19005 103rd Avenue Northeast, Bothell, WA 98011 (US).			
(54) Title: ANTIMICROBIAL COMPOSITIONS			
(57) Abstract <p>Antimicrobial compositions comprising at least two antimicrobial agents exhibit reduced MIC values relative to the MIC for the agents making up the combination when measured alone. The compositions are useful as therapeutic agents such as in oral hygiene products.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ANTIMICROBIAL COMPOSITIONS

Field of the Invention

The present invention relates to antimicrobial compositions, products incorporating such antimicrobial compositions, and applications for antimicrobial compositions.

Background of the Invention

Periodontal disease and dental caries are of major public health and economic interest worldwide. It is now widely recognized that both of these oral diseases are caused by bacteria which grow in masses on the teeth and in the gingival area. A 10 commonly used descriptive term for these bacterial masses is "dental plaque". In the case of periodontal disease, Schluger et al. (Schluger, Yuodelis, Page & Johnson, *Periodontal Diseases*, second edition, pp. 153-262, Lea & Febiger, 1990) report that dental plaque bacteria, growing in the area where the teeth and gingival tissues meet, cause an inflammation of the gingiva called "gingivitis". This is characterized by 15 swollen, edematous gingiva ("gums") which are reddened and bleed easily. If plaque removal is inadequate, gingivitis may progress to "periodontitis" or periodontal disease in many individuals. Periodontitis generally is characterized by a chronic inflammation of the tissues around the teeth, which leads to a resorption of supporting bone. Periodontal disease is the leading cause of tooth loss among adults. 20 Dental caries (cavities) are also caused by bacteria, with *Streptococcus mutans* being the principal etiologic agent (McGhee, Michalek & Cassell, *Dental Microbiology*, p. 279, Harper & Row, 1982).

The prevention of dental plaque or the removal thereof has long been the focus of development, with the ultimate goal of inhibiting both caries and periodontal

5 diseases. While the formation of dental plaque can be inhibited to a certain extent by brushing the teeth at frequent intervals, brushing alone is not sufficient to effectively prevent the formation of dental plaque or remove substantially all of the dental plaque that has formed on the teeth. Since brushing alone is often not sufficient to prevent dental caries or periodontal disease due to pathogenic plaque bacteria, chemical methods using anti-bacterials such as chlorhexidine, benzalkonium chloride, and cetylpyridinium chloride have been proposed.

10 The use of natural products for the treatment of teeth and gums is old in the art, having been practiced and documented since the mid-1880s. Since then, many patents have disclosed compositions of oral products containing natural product extracts.

15 It is known that hinokitiol, citral, geraniol, cocamidopropyl betaine, berberine, and juniper berries oil, individually exhibit antimicrobial properties against certain bacteria.

U.S. Patent No. 3,940,476 describes a method for inhibiting the formation of dental plaque, which comprises topically applying to the teeth as an active ingredient an amount of either one or a combination of (a) allyl isothiocyanate, (b) uranine, (c) obtusastyrene, (d) citral, (e) citronellol, (f) nerol, or (g) geraniol.

20 U.S. Patent No. 4,913,895 describes an oral composition including a linear polyphosphate or a cyclic polyphosphate and menthol, anethol, or mixtures thereof in an aqueous medium. The composition is reported to have antibacterial effects and prevent the development of calculus and periodontal diseases.

25 U.S. Patent No. 4,966,754 describes that certain essential oils and combinations thereof possess antimicrobial properties against *Aspergillus niger*, *Candida albicans*, *Staphylococcus aureus*, and *Pseudomonas aeruginosa* and therefore are useful as preservatives in cosmetic compositions. A blend of 14 essential oils is described as providing desirable antimicrobial properties against the noted microorganisms. The described combination is disclosed as being suitable as a preservative for cosmetic compositions.

30 U.S. Patent No. 4,999,184 describes oil compositions containing certain pyrophosphate salts which are reported to provide an anticalculus benefit.

35 U.S. Patent No. 5,316,760 describes a mouthcare product that contains a combination of *Urtica dioica* extract and an extract of *Juniperus communis*. The combination of these extracts is described as leading to a synergistic reduction of both dental plaque and bleeding or inflammation of the gingiva. *Achillaea*

millefolium extract is also described as being a suitable additive to the combination of the *Urtica dioica* and *Juniperus communis* extracts.

U.S. Patent No. 5,472,684 describes a composition including thymol and eugenol, and optionally a sesquiterpene alcohol, such as farnesol, that reportedly has antiplaque and antigingivitis effects. Australian tea tree oil, sage oil, and eucalyptol are described as enhancing the antiplaque and antigingivitis activity of mouth rinses formulated from the disclosed compositions.

One property that characterizes the effectiveness of an antimicrobial agent as an antiplaque and anticalculus agent is the minimum inhibitory concentration, or MIC, of the agent. The MIC is the minimum concentration in micrograms per milliliter of an antimicrobial agent at which no bacterial growth is observed. At concentrations below the MIC, an antimicrobial agent is ineffective at killing or inhibiting the growth and reproduction of bacteria. At concentrations above the MIC, an antimicrobial agent is effective at killing or inhibiting the growth and reproduction of bacteria.

Typically, antimicrobial agents are introduced into the oral cavity at an initial concentration. Almost immediately, the initial concentration begins to decrease due to the dynamics of the oral cavity. Eventually, the concentration of the antimicrobial agent within the oral cavity will fall below the MIC. Thus, it has been a goal of those working to develop antiplaque and anticalculus formulations to use antimicrobial agents that have low MICs.

Chlorhexidine has a MIC of about one $\mu\text{g}/\text{ml}$ and is the standard against which other antimicrobial agents are measured. While chlorhexidine has a desirable MIC, it also exhibits undesirable taste and has the undesirable side effect of staining teeth.

Summary of the Invention

The present invention relates to the present discovery that the addition of one antimicrobial agent described below to another antimicrobial agent described below results in an unexpected and surprising reduction of the minimum inhibitory concentration (MIC) of at least one of the agents when determined in the combination, i.e., in the presence of the other agent. In other words, the MIC for agent A, when measured in the presence of agent B, is less than the MIC of agent A when measured alone, i.e., in the absence of agent B. Thus, when in combination with agent B, antimicrobial agent A is able to effectively inhibit or prevent bacterial growth at concentrations lower than the MIC for agent A measured alone. When the

combination of agent A and agent B results in the MIC of agent B being reduced to a value lower than the MIC of agent B when evaluated alone, antimicrobial agent B is able to effectively inhibit or prevent bacterial growth at concentrations lower than the MIC for agent B alone. Stated another way, when agents A and B are in combination, at least one of the agents is able to inhibit or prevent the growth of bacteria at a concentration lower than the concentration needed to inhibit or prevent growth of bacteria when only one of the agents of the combination is present.

Compositions for inhibiting the growth of bacteria formed in accordance with the present invention include antimicrobial agent A and antimicrobial agent B in amounts effective to inhibit the growth of bacteria, wherein agent A and agent B are selected from the group consisting of berberine, cedarwood oil, chloramphenicol, citral, citronella oil, cocamidopropyl dimethylglycine, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, juniper berries oil, lemon basil oil, lemon oil, and *Rosmarinus officinalis* oil. An additional composition for inhibiting the growth of bacteria formed in accordance with the present invention includes geraniol and an antimicrobial agent selected from the group consisting of berberine, cedarwood oil, chloramphenicol, citronella oil, cocamidopropyl dimethylglycine, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, juniper berries oil, lemon basil oil, lemon oil, and *Rosmarinus officinalis* oil.

In accordance with the present invention, the minimum inhibitory concentration of agent A in the presence of agent B is less than the minimum inhibitory concentration of agent A alone. In addition, preferably the minimum inhibitory concentration of agent B in the presence of agent A is less than the minimum inhibitory concentration of agent B alone. The compositions of the present invention are effective at inhibiting or preventing the growth of bacteria such as *Actinomyces viscosus*, *Campylobacter rectus*, *Fusobacterium nucleatum*, *Porphyromonas gingivalis*, *Streptococcus mutans*, and *Streptococcus sanguis*.

In addition, compositions formed in accordance with the present invention may include a third antimicrobial agent C different from antimicrobial agent A and antimicrobial agent B, and selected from berberine, cedarwood oil, chloramphenicol, citral, citronella oil, cocamidopropyl dimethylglycine, geraniol, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, juniper berries oil, lemon basil oil, lemon oil, and *Rosmarinus officinalis* oil.

Compositions formed in accordance with the present invention are useful in numerous products such as cleaners, wipes, pharmaceuticals and oral hygiene products. Examples of oral hygiene products include dentifrices and mouth rinses.

5 The compositions for inhibiting the growth of bacteria formed in accordance with the present invention can be used by contacting a surface with the composition.

Brief Description of the Drawings

The FIGURE is a schematic illustration of the dilution scheme in a 96-well plate for a combination of three antimicrobial agents A, B, and C.

Detailed Description of the Preferred Embodiment

10 As used herein, the following terms have the following meanings.

"Berberine" refers to 5,6-dihydro-9,10-dimethoxybenzo[g]-1,3-benzodioxolo [5,6-a] quinolizinium and salts thereof. Berberine is an alkaloid isolated from *Hydrastis canadensis L.* and several other plants in the *Berberidaceae* family. Exemplary salts of berberine include berberine hydrochloride, berberine bisulfate, 15 and berberine sulfate. The Chemical Abstract Service Registry (CAS) number for berberine is 84603-60-1.

20 "Cedarwood oil" refers to volatile whole oil extracts derived principally from the heartwood of *Juniperus virginiana* or *Juniperus ashei*. Constituents of the whole oil extract include thujopsene, cedrol, alpha-copaene, alpha-cedrene, beta-cedrene and widdrol. The CAS number for cedarwood oil is 8000-27-9.

25 "Chloramphenicol" refers to 2,2-dichloro-N-[2-hydroxyl-1-(hydroxymethyl)-2-(4-nitrophenyl) ethyl] acetamide. Chloramphenicol is derived from *Streptomyces venezuelae* or by organic synthesis. The CAS number for chloramphenicol is 56-75-7.

30 "Citral" refers to 3,7-dimethyl-2,6-octadienal. It is the volatile oil of *Cymbopogon citratus* and *Cymbopogon flexuosus* of the *Gramineae* family. Citral is available as a pure compound from commercial sources. The CAS number for citral is 5392-40-5.

35 "Citronella oil" refers to a commercially available oil produced by steam distillation of either *Cymbopogon nardus* or *Cymbopogon winterianus*. The CAS number for citronella oil is 8000-29-1.

"Geraniol" refers to trans-3,7-dimethyl-2,6-octadien-1-ol. The CAS number for geraniol is 106-24-1. Geraniol is found as a constituent in other essential oils such as citronella, lemon grass, rose oil, and palmarosa.

"N-cocamidopropyl-dimethylglycine" has a CAS number of 61789-40-0, 83138-0-3, and 86438-79-1.

5 "Glycyrrhiza glabra extract", also known as licorice root extract, refers to the crude powder extract from *Glycyrrhiza glabra*. Several varieties including *G. typica* and *G. glandulifera* exist. *Glycyrrhiza glabra* extract includes as constituents glycyrrhizic acid and glycyrrhetic acid. The whole extract is available from commercial sources or may be collected by solvent extraction, such as the ethanol extraction described below.

10 "Hinokitiol" refers to beta-thujuplicin, which is an extract of *Thuja plicata*. "Juicy fruit basil oil" refers to the whole extract of a selected variety of basil with a juicy fruit component. Juicy fruit basil is a cultivar of *Ocimum basilicum L.*

15 "Juniper berries oil" refers to volatile whole oil extract from the dried ripe fruit of *Juniperus communis*, *Cupressaceae* family. Juniper berries oil is also known as extract of Juniper, extract of *Juniperus communis*, and Juniper extract. The CAS number for Juniper berries oil is 84603-69-0.

"Lemon basil oil" refers to the volatile whole oil extract from a selected variety of basil with a citral component. Lemon basil is a cultivar of *Ocimum basilicum L* with a high content of citral.

20 "Lemon oil" refers to the volatile whole oil extract from the fresh peel of *Citrus limon*. Lemon oil is also known as oil of lemon or citrus limon oil. The CAS number for lemon oil is 8008-56-8.

25 "Rosmarinus officinalis oil" refers to the whole oil extract from the flowering tops of *Rosmarinus officinalis*. *Rosmarinus officinalis* oil is also known as the extract of Rosemary, or the extract of *Rosmarinus officinalis* oil. The CAS number for *Rosmarinus officinalis* oil is 84604-14-8.

Additional information regarding the essential oils described above can be found in Kirk-Othmer Encyclopedia of Chemical Technology, Fourth Edition, Volume 7, pages 603-674, John Wiley & Sons, Inc.

30 All of the foregoing are available from commercial sources. "Minimal inhibitory concentration or MIC" refers to the minimum concentration in micrograms per milliliter of an antimicrobial agent at which no bacterial growth are observed. At concentrations below the MIC, the antimicrobial agent is ineffective at killing or inhibiting the growth and reproduction of bacteria. At concentrations above the MIC, the antimicrobial agent is effective at killing or 35 inhibiting the growth and reproduction of bacteria.

It has been observed that combinations of antimicrobial agents formed in accordance with the present invention exhibit a surprising and unexpectedly significant decrease in the MIC of at least one, and preferably all of the antimicrobial agents in the combination compared to the MIC of a specific agent of the 5 combination alone, i.e., in the absence of the other agents. This surprising reduction in MIC has been observed relative to representative gram-positive and gram-negative oral pathogenic bacteria such as *Actinomyces viscosus*, *Fusobacterium nucleatum*, *Porphyromonas gingivalis*, *Streptococcus mutans*, *Streptococcus sanguis* and *Campylobacter rectus*. For example, if the MIC for agent A alone is 10 and the MIC 10 for agent B alone is 20, in accordance with the present invention, when agent A and agent B are combined, the MIC of agent A in the presence of agent B decreases relative to the MIC of agent A alone by an unexpected and surprising amount. Furthermore, preferably, the MIC of agent B in the presence of agent A decreases relative to the MIC of agent B alone by an amount that is surprising and unexpected. 15 This reduction in the MIC of agent A and of agent B in the combination translates into the ability of agent A, and preferably agent B, to inhibit and/or prevent the growth and reproduction of bacteria at lower concentrations of antimicrobial agents A and B, compared to if only antimicrobial agent A or only antimicrobial agent B were present. As described in the background of the invention, typically the 20 concentration of antimicrobial agents decreases from the time that the agents are initially applied. Thus, by effectively lowering the MIC of an antimicrobial agent, the period of time during which that antimicrobial agent can be expected to inhibit or prevent the growth of bacteria is extended. The surprising and unexpected results associated with the present invention will be described in more detail below and 25 illustrated in the examples that follow.

Combinations of antimicrobial agents formed in accordance with the present invention include: (1) an antimicrobial agent A selected from berberine, cedarwood oil, chloramphenicol, citral, citronella oil, cocamidopropyl dimethylglycine, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, Juniper berries oil, lemon 30 basil oil, lemon oil, and *Rosmarinus officinalis* oil; and (2) an antimicrobial agent B different from antimicrobial agent A selected from the same list. In addition, combinations formed in accordance with the present invention include geraniol and an antimicrobial agent selected from berberine, cedarwood oil, chloramphenicol, citronella oil, cocamidopropyl dimethylglycine, *Glycyrrhiza glabra* extract,

hinokitiol, juicy fruit basil oil, juniper berries oil, lemon basil oil, lemon oil, and *Rosmarinus officinalis* oil.

Of the many combinations of antimicrobial agents set forth above, preferred combinations include cedarwood oil and an antimicrobial agent selected from 5 berberine, chloramphenicol, citral, cocamidopropyl dimethylglycine, geraniol, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, and *Rosmarinus officinalis* oil. Most preferred are combinations of cedarwood oil with berberine, chloramphenicol, citral, cocamidopropyl dimethylglycine, geraniol, and *Glycyrrhiza glabra* extract.

10 Another preferred set of combinations includes berberine and an antimicrobial agent selected from chloramphenicol, citral, geraniol, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, juniper berries oil, and lemon basil oil. Most preferred for combination with berberine are chloramphenicol, geraniol, *Glycyrrhiza glabra* extract, and lemon basil oil.

15 Other preferred combinations include hinokitiol in combination with chloramphenicol, citral, cocamidopropyl dimethylglycine, geraniol, *Glycyrrhiza glabra* extract, juniper berries oil, and lemon basil oil. Most preferred for combination with hinokitiol are antimicrobial agents selected from chloramphenicol, cocamidopropyl dimethylglycine, geraniol and *Glycyrrhiza glabra* extract.

20 Preferred results are obtained when *Glycyrrhiza glabra* extract is combined with antimicrobial agents selected from cedarwood oil, chloramphenicol, geraniol, juicy fruit basil oil, juniper berries oil, lemon basil oil, lemon oil, and *Rosmarinus officinalis* oil. Most preferred for combination with *Glycyrrhiza glabra* extract are antimicrobial agents selected from cedarwood oil, geraniol, juniper berries oil, 25 *Rosmarinus officinalis* oil.

30 The foregoing combinations of the noted antibacterial agents are preferred and most preferred because of: (1) the degree to which the MIC of the individual antimicrobial agents in the combination is reduced compared to the MIC of those agents when evaluated alone; and (2) the MIC for the individual antimicrobial agents that is achieved due to the combination of agents.

In addition to compositions that include two antimicrobial agents as described above, the present invention also relates to compositions that include more than two, such as three or four antimicrobial agents wherein the MIC of at least one, and preferably all, of the constituent agents in the combination is reduced compared to 35 the MIC of those constituents determined alone. Accordingly, an antimicrobial

agent C selected from the groups set forth above wherein antimicrobial agent C is different from agent A and agent B and can be added to agent A and agent B to provide a three component composition in accordance with the present invention. Combinations of antimicrobial agents A, B and C formed in accordance with the 5 present invention provide compositions wherein the MIC of at least one, and preferably all of the constituent agents, is reduced compared to the MIC of those constituents determined alone. In addition, in some instances, the MIC of the constituents in the combination of three antimicrobial agents is reduced relative to the MIC of various pairings of the three constituent agents.

10 The ratio of antimicrobial agents in compositions formed in accordance with the present invention is not limited to any particular values provided that the reduction in the MIC of the components of the combination is achieved as described above. Ratios for the two component compositions ranging from about 500:1 to about 1:500 have been observed to provide surprising and unexpected reductions in 15 the MICs. In the three component system, any one agent can relate to the other two agents in a range from about 500:1 to about 1:500 to provide reductions in the MIC in accordance with the present invention.

20 The particular amount of antimicrobial agent present in compositions formed in accordance with the present invention is not limited to any particular value, provided that the amount present is effective at retarding the growth of bacteria and/or preventing the growth of bacteria, i.e. in an amount that is greater than the MIC of the antimicrobial agent with respect to the particular bacteria. When the 25 compositions formed in accordance with the present invention are incorporated with various carriers, the amount of the antimicrobial agent present is preferably selected so that once the composition is applied or delivered, the concentration of the antimicrobial agent is greater than the MIC of the antimicrobial agent with respect to a particular bacteria. Suitable amounts range from about 0.001 wt.% to about 5.0 wt.%, preferably about 0.01 wt.% to about 2.5 wt.% for each agent based on the total weight of the composition containing the agents.

30 The compositions formed in accordance with the present invention are applied to surfaces where the inhibition of bacterial growth is desired. Examples of products used to control bacterial growth on surfaces include cleansers, wipes, pharmaceuticals, and preferably therapeutic products such as oral hygiene products, including dentifrices, mouth washes, and mouth rinses. Components of these 35 products that are combined with the compositions of the present invention are

preferably selected so that they do not have an antagonistic effect on the MIC lowering aspect of the compositions formed in accordance with the present invention.

Dentifrices, or toothpastes, are generally a thickened slurry of an abrasive polishing material in an aqueous humectant system. Typically, dentifrices include an abrasive to remove stained pellicle, humectant(s) to provide a vehicle for the flavor, abrasive, thickening agent(s) to structure and stabilize the dentifrice, surfactant mainly to supply foam during use, fluoride to prevent cavities, and flavor to make the product taste pleasant.

Numerous abrasives are available for use in dentifrices, examples include silica xerogel, silica precipitates, dicalcium phosphate, dicalcium phosphate dihydrate, alumina trihydrate, calcium pyrophosphate, calcium carbonate, and insoluble sodium metaphosphate.

Examples of suitable humectants include sorbitols, glycerin, and polyethylene glycols.

Silica aerogels, pyrogenic silica, silica precipitates, carboxymethylcellulose, carboxyvinyl polymers, xanthan gum, and carrageenan are examples of materials that are suitable as thickeners.

Exemplary surfactants include sodium lauryl sulfate and dodecylbenzene sulfonate.

Numerous flavoring agents are commercially available with those providing minty or other refreshing flavors such as cinnamon being commonly used.

Oral rinses or mouth washes are generally, aqueous, pourable emulsions of flavors into which, in most instances, an antimicrobial has been incorporated. Typical components of an oral rinse include flavoring agent to make the product pleasant to use and to emphasize therapeutic or freshness qualities, surfactant(s) to maintain flavor in stable dispersion, humectant(s) to improve mouth feel, thickening agent, and an active agent. Often times, a surfactant is used to impart light foaming properties to the oral rinse.

Dentifrices and oral rinses incorporating the compositions for inhibiting the growth of bacteria formed in accordance with the present invention are formulated in a conventional manner with the antimicrobial agents being present in an amount above their MICs as determined for the combination thereof.

The following examples illustrate the surprising and unexpected reduction in the MIC of the components when these components are combined in compositions for inhibiting the growth of bacteria formed in accordance with the present invention.

Example 1Determination of Minimum Inhibitory Concentration of Individual Agents and Two Antimicrobial Agents in Combination

The following example illustrates how the MIC of individual antimicrobial agents that are combined to form a composition in accordance with the present invention were determined and also illustrates how the MIC of the antimicrobial agents in combination were determined.

A microtiter plate was used to dilute the antimicrobial agents to varying concentrations in order to determine the MIC of those antimicrobial agents alone and the MIC of the agents when combined to form a composition in accordance with the present invention.

A bacterial culture was incubated at 37°C. Prior to the dilution of the antimicrobial agents as described below, the bacterial culture was spun down at 2,000 rpm into a pellet and resuspended in a solution of buffered phosphate. The inoculum was normalized with a spectrophotometer to an optical density at 550 nanometers of between 0.180-0.220 (equivalent to 5.0×10^7 colony forming units, CFU per milliliter). The inoculum was set aside until the completion of the antimicrobial agent dilution.

A sterile polystyrene 96-well plate was used to dilute combinations of antimicrobial agent A and antimicrobial agent B. Using aseptic technique, 100 microliters of distilled water was placed in each test well. The dilution scheme of the antimicrobial agents was separated into two parts, the first part being the dilution of agent A and the second part being the dilution of agent B. One hundred microliters of stock solution for agent A was placed in the first well of each column. This was a one-half dilution based on the concentration of the stock solution. One hundred microliters was then transferred to the next well and so on down each of the test wells. Each transfer was a one-half dilution of the preceding well concentration. One hundred microliters of agent B stock solution was then added to the first well of each row and diluted across the plate in the same manner that agent A was diluted down the plate. After the dilution of agent B was completed, 80 microliters of growth media specific for the bacteria under study was added to each well.

In one column of the plate, 100 microliters of stock solution for agent A was placed in the first well. 100 microliters was then transferred to the next well and so on down each of the test wells in the column. Each transfer was a 1/2 dilution of the

preceding well concentration of agent A. The foregoing was replicated in another column using agent B. These two columns were used to determine the MIC for agent A alone and agent B alone. After dilution of agent A alone and agent B alone was completed, 80 microliters of growth media specific for the bacteria under study was 5 added to each well in these two columns.

Twenty microliters of innoculum was then added to each well. This resulted in the first well having a final dilution of one-quarter based on the concentration of the stock solutions. The remaining wells were a one-half dilution of the preceding well for each transfer. The 96-well plate was incubated under conditions that varied 10 based on the particular microorganism. The aerobic bacteria *Actinomyces viscosus*, *Streptococcus mutans* and *Streptococcus sanguis* were incubated under ambient room conditions. The anaerobic bacteria *Fusobacterium nucleatum* and *Porphyromonas gingivalis* were incubated under an atmosphere of 10% hydrogen, 5% carbon dioxide and the balance nitrogen gas.

15 Following 48 hours of incubation, the incubated plate was read for microbial growth with a spectrophotometer by optical density (OD). The well containing the lowest dilution achievable for each agent with a spectrophotometer reading below 0.05 OD (i.e., no detectable microbial growth) was considered representative for the combination. The MIC for each agent in the combination was determined by 20 accounting for the starting stock solution concentration and the resulting dilutions in the 96-well plate.

The specific bacteria inoculated into the 96-well plate are set forth in Table 1 below along with the growth media and the incubation conditions for that microorganism.

Table 1
Microorganisms/Growth Media/Incubation Conditions

Microorganism	ATCC No.	Growth Media	Incubation Conditions
<i>Actinomyces viscosus</i> (AV)	19246	TSB ¹	48 hrs/37°C/aerobic
<i>Fusobacterium nucleatum</i> (FN)	10933	FN media ³	48 hrs/37°C/anaerobic
<i>Porphyromonas gingivalis</i> (PG)	33277	PG media ²	48 hrs/37°C/anaerobic
<i>Streptococcus mutans</i> (SM)	25175	TSB ¹	48 hrs/37°C/aerobic
<i>Streptococcus sanguis</i> (SS)	49295	TSB ¹	48 hrs/37°C/aerobic

1 Tryptic Soy Broth 3.0% wt. to vol., yeast extract 0.1%, and 999 milliliters distilled water.
 5 2 Tryptic Soy Broth 3.0% wt. to vol., yeast extract 0.5%, L-cystein 0.05%, Hemin 0.0005%, Menadione 0.00002%, and 990 milliliters distilled water.
 3 Tryptic Soy Broth 3.0% wt. to vol., yeast extract 0.5%, Peptone 1.0%, L-cystein extract, Hemin 0.0005%, Menadione 0.00002%, and 990 milliliters distilled water.

10 The antimicrobial agents from which agent A and agent B were selected are set forth in Table 2 below.

Table 2

Berberine hydrochloride (BX1)
 Cedarwood oil (RC1)
 Chloramphenicol (CR1)
 15 Citral (CIT1)
 Citronella oil (CTR1)
 Cocamidopropyl dimethylglycine (TB1)
 Geraniol (GRA1)
 Glycyrrhiza glabra extract (GLY)
 20 Hinokitiol (HK1)
 Juicy fruit basil oil (JFB1)
 Juniper berries oil (JPE1)
 Lemon basil oil (LMB1)
 Lemon oil (LMO1)
 25 Rosmarinus officinalis oil (ROF1)

In the following tables, the respective antimicrobial agents A and B are identified with respect to the abbreviations set forth in Table 2. In addition, the five microorganisms set forth in Table 1 are referred to by the abbreviations set forth in Table 1.

Various combinations of the antimicrobial agents set forth in Table 2 were evaluated in accordance with the protocol set forth above in order to identify combinations of agents that will inhibit visible *in vitro* growth of microorganisms and evaluate the MIC of the agents in the combination. In addition, the lowest 5 concentration, e.g., (MIC), of each of the antimicrobial agents used in the two component combinations that inhibited visible *in vitro* growth of a particular microorganism was determined in accordance with the protocol set forth above. The resulting data are summarized in Tables 3-16. In each of these tables, a mean MIC value is given for agent A alone. Because multiple well plates were inoculated and 10 incubated in accordance with the procedure above in order to ascertain the information regarding the multiple combinations, in each run, a MIC for agent A alone was determined. The MIC for agent A alone given in Tables 3-16 represents the mean of these values.

Table 3

15 MIC of Cedarwood Oil Alone and in Combination with Antimicrobial Agent B

Agent		MIC ($\mu\text{g}/\text{ml}$) of Cedarwood Oil When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
RCI	--	36.5	36.5	7.8	31.3	15.6
	+BX1	7.8	2.0	2.0	7.8	2.0
	+CR1	7.8	3.9	2.0	2.0	7.8
	+CIT1	7.8	7.8	3.9	7.8	2.0
	+CTR1	2.0	15.6	3.9	7.8	7.8
	+TB1	7.8	15.6	2.0	7.8	31.3
	+GRA1	3.9	7.8	2.0	7.8	2.0
	+GLY	7.8	15.6	3.9	7.8	3.9
	+HK1	15.6	15.6	3.9	7.8	7.8
	+JFB1	7.8	15.6	3.9	2.0	3.9
	+JPE1	2.0	15.6	3.9	7.8	7.8

Agent		MIC ($\mu\text{g/ml}$) of Cedarwood Oil When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
	+LMB1	2.0	2.0	3.9	7.8	3.9
	+LMO1	7.8	15.6	3.9	7.8	3.9
	+ROF1	15.6	15.6	3.9	3.9	7.8

Table 4
MIC of Berberine Hydrochloride Alone and in Combination With Antimicrobial Agent B

5

Agent		MIC ($\mu\text{g/ml}$) of Berberine Hydrochloride When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
BX1	--	31.9	38.5	11.4	43.3	46.9
	+RC1	3.9	15.6	7.8	3.9	7.8
	+CR1	3.9	15.6	7.8	2.0	3.9
	+CIT1	2.0	7.8	2.0	15.6	15.6
	+CTR1	7.8	2.0	3.9	2.0	3.9
	+TB1	31.3	31.3	7.8	31.3	15.6
	+GRA1	3.9	7.8	2.0	7.8	15.6
	+GLY	15.6	15.6	7.8	15.6	15.6
	+HK1	7.8	15.6	2.0	31.3	3.9
	+JFB1	15.6	15.6	2.0	15.6	15.6
	+JPE1	2.0	7.8	7.8	2.0	3.9
	+LMB1	2.0	7.8	2.0	3.9	7.8
	+LMO1	2.0	2.0	2.0	15.6	7.8
	+ROF1	31.3	2.0	3.9	31.3	2.0

Table 5
MIC of Hinokitiol Alone and in Combination With Antimicrobial Agent B

Agent		MIC (μ g/ml) of Hinokitiol When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
HK1	--	0.8	2.1	2.1	0.8	0.9
	+BX1	0.2	0.4	1.6	0.1	0.4
	+RC1	0.2	0.8	0.1	0.2	0.1
	+CR1	0.2	0.8	0.4	0.2	0.2
	+CIT1	0.4	0.8	0.8	0.4	0.4
	+CTR1	0.1	0.1	0.8	0.1	0.4
	+TB1	1.0	1.0	7.8	1.0	1.0
	+GRA1	0.1	0.8	0.8	0.8	0.2
	+GLY	0.4	0.8	0.8	0.8	0.8
	+JFB1	0.4	0.4	0.4	0.4	0.4
	+JPE1	0.1	0.2	0.2	0.1	0.4
	+LMB1	0.1	0.4	0.2	0.1	0.1
	+LMO1	0.1	0.2	0.8	0.1	0.2
	+ROF1	0.1	0.1	0.2	0.1	0.4

Table 6
MIC of *Glycyrrhiza glabra* Extract Alone and in Combination With
Antimicrobial Agent B

5

Agent		MIC (µg/ml) of <i>Glycyrrhiza glabra</i> Extract When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
GLY	--	15.0	15.6	12.1	15.6	6.6
	+BX1	7.8	3.9	1.0	7.8	3.9
	+RC1	3.9	2.0	2.0	3.9	3.9
	+CR1	1.0	1.0	1.0	3.9	2.0
	+CIT1	1.0	1.0	2.0	1.0	1.0
	+CTR1	3.9	2.0	3.9	3.9	1.0
	+TB1	1.0	1.0	7.8	15.6	1.0
	+GRA1	3.9	3.9	3.9	3.9	1.0
	+HK1	7.8	3.9	1.0	1.0	1.0
	+JFB1	1.0	2.0	2.0	1.0	2.0
	+JPE1	3.9	2.0	3.9	1.0	1.0
	+LMB1	3.9	3.9	2.0	3.9	1.0
	+LMO1	2.0	2.0	2.0	3.9	1.0
	+ROF1	1.0	2.0	1.0	1.0	2.0

-18-

Table 7
MIC of Geraniol Alone and in Combination With Antimicrobial Agent B

Agent		MIC (µg/ml) of Geraniol When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
GRA1	--	133.3	82.3	147.9	133.3	127.1
	+BX1	31.3	31.3	31.3	31.3	31.3
	+RC1	62.5	15.6	15.6	31.3	31.3
	+CR1	62.5	31.3	31.3	62.5	31.3
	+CTR1	15.6	15.6	31.3	31.3	15.6
	+TB1	12.5	31.3	31.3	125	62.5
	+GLY	62.5	15.6	3.9	62.5	31.3
	+HK1	31.3	15.6	15.6	3.9	62.5
	+JFB1	7.8	31.3	15.6	31.3	31.3
	+JPE1	31.3	15.6	62.5	31.3	15.6
	+LMB1	31.3	15.6	62.5	31.3	31.3
	+LMO1	31.3	7.8	62.5	31.3	31.3
	+ROF1	31.3	31.3	15.6	31.3	31.3

5

Table 8
MIC of Chloramphenicol Alone and in Combination With Antimicrobial Agent B

Agent		MIC (µg/ml) of Chloramphenicol When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
CR1	--	5.4	1.8	6.9	5.2	3.2
	+BX1	3.1	0.2	0.2	3.1	3.1

Agent		MIC (µg/ml) of Chloramphenicol When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
	+RC1	0.4	1.6	0.8	3.1	0.8
	+CIT1	0.2	0.2	0.2	0.2	0.4
	+CTR1	1.6	0.4	3.1	1.6	1.6
	+TB1	1.6	0.4	1.6	3.1	0.8
	+GRA1	0.4	0.2	0.2	0.8	0.4
	+GLY	3.1	0.8	0.4	1.6	0.8
	+HK1	3.1	0.8	0.4	3.1	3.1
	+JFB1	0.2	0.4	1.6	3.1	0.4
	+JPE1	1.6	0.2	1.6	0.2	0.2
	+LMB1	1.6	0.4	0.4	3.1	0.2
	+LMO1	1.6	0.2	0.2	1.6	0.8
	+ROF1	0.2	0.2	3.1	0.2	0.2

Table 9
MIC of Citral Alone and in Combination With Antimicrobial Agent B

Agent		MIC (µg/ml) of Citral When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
CIT1	--	212.5	76.1	75.0	171.1	147.9
	+BX1	31.3	31.3	15.6	31.3	31.3
	+RC1	125	125	62.5	125	125
	+CR1	62.5	31.3	15.6	62.5	31.3
	+CTR1	7.8	3.9	15.6	15.6	15.6
	+TB1	125	31.3	31.3	62.5	31.3
	+GLY	125	31.3	15.6	125	7.8

-20-

Agent		MIC (µg/ml) of Citral When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
	+HK1	15.6	3.9	15.6	31.3	15.6
	+JFB1	15.6	15.6	15.6	15.6	15.6
	+JPE1	31.3	15.6	31.3	31.3	3.3
	+LMB1	15.6	7.8	7.8	31.3	31.3
	+LMO1	31.3	15.6	7.8	15.6	3.9
	+ROF1	62.5	15.6	31.3	62.5	3.9

Table 10
MIC of Citronella Oil Alone and in Combination With Antimicrobial Agent B

Agent		MIC (µg/ml) of Citronella Oil When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
CTR1	--	119.8	76.9	198.4	138.4	156.2
	+BX1	31.3	31.3	7.8	62.5	31.3
	+RC1	62.5	7.8	3.9	31.3	31.3
	+CR1	31.3	15.6	15.6	31.3	3.9
	+CIT1	62.5	15.6	15.6	62.5	62.5
	+TB1	62.5	31.3	31.3	125	31.3
	+GRA1	31.3	31.3	31.3	31.3	31.3
	+GLY	31.3	31.3	15.6	31.3	62.5
	+HK1	62.5	31.3	3.9	62.5	7.8
	+JFB1	31.3	15.6	31.3	31.3	31.3
	+JPE1	31.3	7.8	31.3	31.3	31.3
	+LMB1	3.9	15.6	31.3	7.8	7.8
	+LMO1	3.9	15.6	31.3	15.6	15.6
	+ROF1	31.3	15.6	15.6	31.3	7.8

Table 11

MIC of Juicy Fruit Basil Oil Alone and in Combination With Antimicrobial Agent B

Agent		MIC (µg/ml) of Juicy Fruit Basil Oil When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
JFB1	--	89.6	73.7	36.9	95.8	93.8
	+BX1	62.5	31.3	3.9	31.3	15.6
	+RC1	62.5	31.3	3.9	62.5	31.3
	+CR1	31.3	3.9	3.9	3.9	31.3
	+CIT1	15.6	15.6	15.6	31.3	31.3
	+CTR1	15.6	15.6	3.9	15.6	15.6
	+TB1	31.3	31.3	15.6	62.5	62.5
	+GRA1	31.3	15.6	15.6	15.6	31.3
	+GLY	62.5	31.3	15.6	62.5	31.3
	+HK1	62.5	31.3	3.9	62.5	31.3
	+JPE1	15.6	3.9	3.9	7.8	15.6
	+LMB1	15.6	3.9	7.8	31.3	15.6
	+LMO1	15.6	15.6	15.6	15.6	31.3
	+ROF1	15.6	3.9	3.9	15.6	15.6

5

Table 12

MIC of Juniper Berries Oil Alone and in Combination With Antimicrobial Agent B

Agent		MIC (µg/ml) of Juniper Berries Oil When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
JPE1	--	135.4	76.9	231.8	119.8	119.3
	+BX1	31.3	31.3	7.8	62.5	31.3
	+RC1	62.5	15.6	3.9	31.3	31.3
	+CR1	31.3	7.8	15.6	62.5	31.3
	+CIT1	62.5	15.6	7.8	62.5	31.3
	+CTR1	31.3	15.6	31.3	31.3	31.3
	+TB1	125	31.3	15.6	62.5	62.5

-22-

Agent		MIC (µg/ml) of Juniper Berries Oil When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
	+GRA1	31.3	15.6	31.3	31.3	31.3
	+GLY	62.5	31.3	62.5	62.5	31.3
	+HK1	62.5	31.3	7.8	62.5	15.6
	+JFB1	31.3	15.6	62.5	31.3	31.3
	+LMB1	31.3	15.6	62.5	31.3	31.3
	+LMO1	31.3	15.6	62.5	15.6	31.3
	+ROF1	62.5	15.6	31.3	31.3	15.6

Table 13
MIC of Lemon Basil Oil Alone and in Combination With Antimicrobial Agent B

Agent		MIC (µg/ml) of Lemon Basil Oil When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
LMB1	--	125	81.7	200.5	130.2	132.8
	+BX1	31.3	15.6	7.8	31.3	15.6
	+RC1	62.5	31.3	3.9	15.6	31.3
	+CR1	31.3	15.6	31.3	7.8	62.5
	+CIT1	62.5	15.6	15.6	62.5	31.3
	+CTR1	62.5	15.6	15.6	62.5	62.5
	+TB1	62.5	15.6	15.6	62.5	31.3
	+GRA1	15.6	15.6	31.3	31.3	15.6
	+GLY	31.3	15.6	31.3	62.5	15.6
	+HK1	31.3	15.6	7.8	31.3	31.3
	+JFB1	31.3	15.6	15.6	31.3	31.3
	+JPE1	31.3	15.6	62.5	31.3	15.6
	+LMO1	31.3	15.6	15.6	31.3	31.3
	+ROF1	15.6	31.3	31.3	31.3	31.3

-23-

Table 14
MIC of Lemon Oil Alone and in Combination With Antimicrobial Agent B

Agent		MIC ($\mu\text{g/ml}$) of Lemon Oil When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
LMO1	--	173.6	79.9	367.2	153.4	127.9
	+BX1	62.5	31.3	15.6	62.5	31.3
	+RC1	62.5	15.6	3.9	62.5	62.5
	+CR1	31.3	15.6	15.6	31.3	31.3
	+CIT1	62.5	15.6	31.3	62.5	62.5
	+CTR1	62.5	15.6	15.6	62.5	62.5
	+TB1	125	15.6	62.5	125	62.5
	+GRA1	31.3	7.8	15.6	31.3	31.3
	+GLY	62.5	31.3	15.6	62.5	31.3
	+HK1	125	31.3	7.8	125	62.5
	+JFB1	15.6	15.6	31.3	31.3	31.3
	+JPE1	31.3	15.6	31.3	31.3	31.3
	+LMB1	31.3	15.6	15.6	31.3	31.3
	+ROF1	31.3	31.3	31.3	31.3	31.3

5

Table 15
MIC of *Rosmarinus officinalis* Oil Alone and in Combination With Antimicrobial Agent B

Agent		MIC ($\mu\text{g/ml}$) of <i>Rosmarinus officinalis</i> Oil When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
ROF1	--	192.3	72.1	184.9	174.1	132.8
	+BX1	31.3	31.3	15.6	31.3	62.5
	+RC1	7.8	15.6	7.8	62.5	31.3
	+CR1	62.5	31.3	15.6	62.5	31.3
	+CIT1	62.5	15.6	31.3	62.5	62.5
	+CTR1	15.6	31.3	62.5	31.3	31.3

Agent		MIC ($\mu\text{g/ml}$) of <i>Rosmarinus officinalis</i> Oil When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
	+TB1	125	31.3	62.5	125	31.3
	+GRA1	31.3	15.6	31.3	31.3	31.3
	+GLY	125	31.3	15.6	125	7.8
	+HK1	125	31.3	7.8	125	15.6
	+JFB1	31.3	15.6	31.3	31.3	31.3
	+JPE1	31.3	15.6	15.6	31.3	31.3
	+LMB1	31.3	15.6	15.6	31.3	31.3
	+LMO1	15.6	15.6	125	15.6	31.3

Table 16
MIC of Cocamidopropyl Dimethylglycine Alone and in Combination
With Antimicrobial Agent B

5

Agent		MIC ($\mu\text{g/ml}$) of Cocamidopropyl Dimethylglycine When Combined With Agent B for Identified Bacteria				
A	B	AV	FN	PG	SM	SS
TB1	--	28.9	45.4	16.8	22.8	30.2
	+BX1	1.0	1.0	7.8	1.0	15.6
	+RC1	1.0	7.8	2.0	1.0	0.1
	+CR1	31.3	31.3	3.9	15.6	31.3
	+CIT1	1.0	7.8	2.0	1.0	15.6
	+CTR1	7.8	1.0	2.0	1.0	1.0
	+GRA1	1.0	15.6	2.0	1.0	7.8
	+GLY	15.6	62.5	3.9	1.0	31.3
	+HK1	1.0	1.0	7.8	1.0	1.0
	+JFB1	7.8	1.0	1.0	3.9	1.0
	+JPE1	1.0	1.0	2.0	1.0	1.0
	+LMB1	3.9	1.0	3.9	1.0	1.0
	+LMO1	1.0	3.9	3.9	1.0	1.0
	+ROF1	3.9	1.0	2.0	1.0	3.9

This example illustrates the effect that the addition of an antimicrobial agent B to antimicrobial agent A has on the MIC of antimicrobial agent A. The resulting data illustrate how the MIC of agent A when combined with agent B is reduced relative to the MIC of agent A alone.

5

Example 2
Determination of MIC of Individual Agents and
Three Antimicrobial Agents in Combination

This example illustrates how combinations of three antimicrobial agents formed in accordance with the present invention inhibit visible *in vitro* growth of oral 10 microorganisms. In addition, the example describes how the MIC of antimicrobial agents in the combinations are reduced compared to the MIC of those antimicrobial agents alone and the MIC of those agents in various pairings. Numerous 15 combinations of the antimicrobial agents described herein were combined to form combinations comprising three antimicrobial agents or triplets. Each of the formed triplets included either cedarwood oil, berberine hydrochloride, or hinokitiol.

The protocol used was a variation of the procedure described above in Example 1. The assay was carried out in the two-dimensional array of a 96-well plate. In order to evaluate three agents, two of the agents were paired against the third agent. For example, varying concentrations of antimicrobial agent A plus 20 antimicrobial agent B versus varying concentrations of antimicrobial agent C were evaluated on one 96-well plate. The procedure was repeated with the other two possible pairings, i.e., A+C with B, and B+C with A. Accordingly, each triplet required three assays in order to assess each of the three possible pairings.

The bacterial inoculum was prepared as described in Example 1.

25 A sterile polystyrene 96-well plate was used to dilute the antimicrobial agents A, B and C. Using aseptic technique, 100 microliters of distilled water was placed in each test well. The dilution scheme was separated into two parts. First, the dilution of the combined agents A and B and then second, the dilution of agent C. A dilution of agents A and B was accomplished by placing 50 microliters of stock 30 solution for agent A in the first well of each column. Next, 50 microliters of stock solution for agent B was added to each of the first wells of each column. Accordingly, the first well of each column included 50 microliters of stock solution for agent A and 50 microliters of stock solution for agent B. 100 microliters from the first row in each column was then transferred to the next well in the column and so

on down the column. Each transfer was a one-half dilution of the preceding concentration.

The dilution of antimicrobial agent C was accomplished by adding 100 microliters of agent C stock solution to the first well of each row. 5 100 microliters from the first well in each row was then transferred to the next well and so on across the row of test wells. Each transfer was a one-half dilution of the preceding concentration. The FIGURE is a schematic illustration of the concentrations of antimicrobial agents A, B and C derived from the dilution scheme described above. The stock solution for each antimicrobial agent had an initial 10 concentration of 2,500 micrograms per milliliter. As illustrated in the FIGURE, the concentration of agents A and B decreases down a given column. The concentration of agent C decreases across a row from left to right. Upon completion of the dilution of agent C, at least one column remained which included diluted stock solution of A and B, with any agent C. This column of wells was used to assess the MIC for agent 15 A and agent B in combination. In addition, stock solution of agent C was diluted down one column which provided an indication of the MIC for agent C alone. 80 microliters of growth media specific for the bacteria under study was added to each well. The growth media specific for the bacteria are set forth above in Table 1.

Next, 20 microliters of innoculum was added to each well. This resulted in 20 the first well having a final dilution one-eighth of the stock solutions for agent A and agent B, and one-quarter dilution of the stock solution for agent C. The remaining wells were a half-dilution of the preceding well for each transfer.

The 96-well plate was then incubated under conditions that varied by 25 microorganism. Table 1 lists the microorganisms and the specific incubation conditions. In addition to the bacteria set forth in Table 1, the bacteria *Campylobacter rectus* (CR) was utilized. The growth media for *Campylobacter rectus* was 0.74% wt. to vol. brain heart infusion broth, 0.01% yeast extract, 0.2% sodium formate, 0.03% sodium fumerate, and 0.005% hemin, and 990 milliliters distilled water. The incubation conditions for *Campylobacter rectus* were 48 hours at 30 37°C under anaerobic conditions. The plate was then read for microbial growth with a spectrophotometer by optical density. The well containing the lowest dilution achievable for each agent with a spectrophotometer reading below 0.05 OD was considered representative for the combination. The MIC for each agent was then determined by accounting for the starting stock solution concentration and the 35 resulting dilutions in the 96 well plate.

The resulting data are summarized in Tables 17-35.

Table 17
MIC of Cedarwood Oil, Citral and Geraniol Alone, in Pairs, and in Combination

5

Individual Agents Alone ¹			MIC (μ g/ml) for Identified Bacteria				
A	B	C	AV	FN	PG	SM	SS
RC1	--	--	31.3	31.3	15.6	15.6	125
--	CIT1	--	125	62.5	62.5	125	125
--	--	GRA1	125	62.5	62.5	125	125
Pairings of Agents A, B & C ²							
RC1			15.6	15.6	7.8	15.6	31.3
+CIT1			31.3	31.3	15.6	31.3	62.5
RC1			15.6	15.6	7.8	15.6	31.3
+GRA1			31.3	31.3	15.6	31.3	62.5
CIT1			62.5	31.3	31.3	62.5	62.5
+GRA1			62.5	31.3	31.3	62.5	62.5
Triplets of Agents A, B & C ³							
GRA1			7.8	31.3	15.6	3.9	31.3
+RC1			7.8	1	1	7.8	3.9
+CIT1			15.6	2	2	15.6	7.8
CIT1			3.9	15.6	15.6	3.9	7.8
+RC1			7.8	3.9	1	7.8	7.8
+GRA1			15.6	7.8	2	15.6	15.6
RC1			7.8	15.6	3.9	7.8	7.8
+CIT			7.8	7.8	7.8	3.9	15.6
+GRA1			7.8	7.8	7.8	3.9	15.6

¹ Directly to the right is shown the MIC values for each agent when used alone.

² Directly to the right is shown the MIC values for each agent in the presence of a second agent.

³ Directly to the right is shown the MIC values for each agent in the presence of two additional agents.

10

Table 18
MIC of Cedarwood Oil, Berberine Hydrochloride and Geraniol
Alone, in Pairs, and in Combination

Individual Agents Alone ¹			MIC (µg/ml) for Identified Bacteria				
A	B	C	AV	FN	PG	SM	SS
RC1	--	--	31.3	62.5	15.6	31.3	7.8
--	BX1	--	31.3	62.5	15.6	31.3	31.3
--	--	GRA1	125	62.5	62.5	125	125
Pairings of Agents A, B & C ²							
RC1			15.6	15.6	7.8	15.6	3.9
+BX1			15.6	15.6	7.8	15.6	3.9
RC1			15.6	15.6	7.8	15.6	7.8
+GRA1			31.3	31.3	15.6	31.3	15.6
BX1			31.3	31.3	15.6	15.6	31.3
+GRA1			62.5	31.3	31.3	31.3	62.5
Triplets of Agents A, B & C ³							
RC1			7.8	15.6	3.9	7.8	3.9
+BX1			3.9	7.8	3.9	2.0	3.9
+GRA1			7.8	7.8	7.8	3.9	7.8
BX1			3.9	7.8	7.8	7.8	7.8
+RC1			7.8	3.9	1.0	7.8	3.9
+GRA1			15.6	7.8	2.0	15.6	7.8
GRA1			7.8	15.6	15.6	31.3	31.3
+RC1			7.8	3.9	1.0	7.8	1.0
+BX1			7.8	3.9	1.0	7.8	1.0

Table 19

MIC of Red Cedarwood Oil, Berberine Hydrochloride and Hinokitiol Alone, in Pairs, and in Combination

Individual Agents Alone ¹			MIC (µg/ml) for Identified Bacteria				
A	B	C	AV	FN	PG	SM	SS
RC1	--	--	31.3	62.5	15.6	31.3	31.3
--	BX1	--	31.3	62.5	15.6	31.3	31.3
--	--	HK1	0.8	1.6	3.1	0.8	0.8
Pairings of Agents A, B & C ²							
RC1			15.6	15.6	7.8	15.6	3.9
+BX1			15.6	15.6	7.8	15.6	3.9
RC1			15.6	15.6	15.6	15.6	15.6
+HK1			0.8	0.8	0.4	0.8	0.4
BX1			15.6	15.6	15.6	15.6	15.6
+HK1			0.8	0.8	7.8	0.8	7.8
Triplets of Agents A, B & C ³							
RC1			15.6	7.8	3.9	7.8	3.9
+BX1			1.0	3.9	3.9	3.9	3.9
+HK1			0.05	0.2	2	0.2	2
RC1			3.9	15.6	7.8	7.8	15.6
+RC1			7.8	1.0	1.0	7.8	1.0
+HK1			0.4	0.05	0.05	0.4	0.05
HK1			0.2	0.4	0.8	0.2	0.4
+RC1			7.8	3.9	3.9	7.8	1.0
+BX1			7.8	3.9	3.9	7.8	1.0

Table 20
MIC of Red Cedarwood Oil, Berberine Hydrochloride and Juicy Fruit Basil Oil
Alone, in Pairs, and in Combination

5

Individual Agents Alone ¹			MIC (µg/ml) for Identified Bacteria				
A	B	C	AV	FN	PG	SM	SS
RC1	--	--	15.6	31.3	62.5	15.6	15.6
--	BX1	--	62.5	62.5	15.6	31.3	62.5
--	--	JFB1	125	62.5	62.5	125	125
Pairings of Agents A, B & C ²							
RC1			15.6	15.6	7.8	15.6	7.8
BX1			15.6	15.6	7.8	15.6	7.8
RC1 +JFB1			7.8 15.6	2.0 31.3	1.0 2.0	7.8 15.6	1.0 2.0
BX1 +JFB1			31.3 62.5	15.6 31.3	7.8 15.6	15.6 31.3	15.6 31.3
Triplets of Agents A, B & C ³							
RC1			7.8	7.8	7.8	7.8	7.8
BX1			15.6	3.9	2.0	7.8	3.9
+JFB1			31.3	7.8	3.9	15.6	7.8
BX1			15.6	15.6	3.9	7.8	31.3
RC1			7.8	2.0	1.0	7.8	1.0
+JFB1			15.6	3.9	2.0	15.6	2.0
JFB1			62.5	15.6	15.6	62.5	62.5
+RC1			1.0	2.0	2.0	1.0	2.0
+BX1			1.0	3.9	2.0	1.0	2.0

Table 21
MIC of Cedarwood Oil, Hinokitiol and Geraniol
Alone, in Pairs, and in Combination

5

Individual Agents Alone ¹			MIC (μ g/ml) for Identified Bacteria				
A	B	C	AV	FN	PG	SM	SS
RC1	--	--	7.8	62.5	7.8	15.6	15.6
--	HK1	--	0.8	3.1	1.6	0.8	0.8
--	--	GRA1	125	125	62.5	125	125
Pairings of Agents A, B & C ²							
RC1			15.6	15.6	15.6	15.6	7.8
+HK1			0.8	0.8	0.8	0.8	0.4
RC1			31.3	15.6	7.8	7.8	15.6
+GRA1			62.5	31.3	15.6	15.6	31.3
HK1			0.8	0.8	0.8	0.8	0.8
+GRA1			31.3	31.3	31.3	31.3	31.3
Triplets of Agents A, B & C ³							
RC1			3.9	15.6	3.9	3.9	7.8
+HK1			0.2	0.05	0.1	0.1	0.05
+GRA1			7.8	2.0	3.9	3.9	2.0
HK1			0.1	1.6	0.4	0.4	0.1
+RC1			15.6	2.0	2.0	2.0	7.8
+GRA1			31.3	3.9	3.9	3.9	15.6
GRA1			15.6	31.3	62.5	7.8	62.5
+RC1			7.8	2.0	3.9	7.8	1.0
+HK1			0.4	0.1	0.2	0.4	0.5

Table 22
MIC of Cedarwood Oil, Hinokitiol and Citral
Alone, in Pairs, and in Combination

5

Individual Agents Alone ¹			MIC (µg/ml) for Identified Bacteria				
A	B	C	AV	FN	PG	SM	SS
RC1	--	--	7.8	62.5	15.6	15.6	15.6
--	HK1	--	0.8	3.1	1.6	0.8	1.6
--	--	CIT1	125	125	62.5	125	125
Pairings of Agents A, B & C ²							
RC1			15.6	15.6	7.8	15.6	7.8
+HK1			0.8	0.8	0.4	0.8	0.8
RC1			31.3	15.6	7.8	15.6	15.6
+CIT1			62.5	31.3	15.6	31.3	31.3
HK1			0.8	0.8	0.4	0.8	0.8
+CIT1			31.3	31.3	15.6	31.3	31.3
Triplets of Agents A, B & C ³							
RC1			3.9	15.6	3.9	3.9	7.8
+HK1			0.2	0.05	0.1	0.2	0.1
+CIT1			7.8	2.0	3.9	7.8	3.9
HK1			0.1	0.8	0.4	0.4	0.4
+RC1			15.6	3.9	2.0	7.8	3.9
+CIT1			31.3	7.8	3.9	15.6	7.8
CIT1			7.8	31.3	3.9	7.8	62.5
+RC1			7.8	2.0	3.9	7.8	1.0
+HK1			0.4	0.1	0.2	0.4	0.1

Table 23
MIC of Cedarwood Oil, Hinokitiol and Juicy Fruit Basil Oil
Alone, in Pairs, and in Combination

Individual Agents Alone ¹			MIC (µg/ml) for Identified Bacteria				
A	B	C	AV	FN	PG	SM	SS
RC1	--	--	7.8	62.5	7.8	31.3	15.6
--	HK1	--	0.8	3.1	3.1	0.8	0.8
--	--	JFB1	125	125	15.6	62.5	125
Pairings of Agents A, B & C ²							
RC1			15.6	15.6	7.8	15.6	7.8
+HK1			0.8	0.8	0.4	0.8	0.4
RC1			31.3	15.6	3.9	15.6	15.6
+JFB1			62.5	31.3	7.8	31.3	31.3
HK1			0.8	0.8	0.4	0.8	0.4
+JFB1			31.3	31.3	15.6	31.3	15.6
Triplets of Agents A, B & C ³							
RC1			3.9	15.6	3.9	15.6	7.8
+HK1			0.4	0.2	0.1	0.05	0.1
+JFB1			15.6	7.8	3.9	2.0	3.9
HK1			0.2	0.8	0.8	0.4	0.4
+RC1			7.8	3.9	1.0	7.8	2.0
+JFB1			15.6	7.8	2.0	15.6	3.9
JFB1			62.5	31.3	7.8	15.6	31.3
+RC1			3.9	3.9	1.0	7.8	2.0
+HK1			0.2	0.2	0.05	0.4	0.1

Table 24
MIC of Cedarwood Oil, Berberine Hydrochloride and Citral
Alone, in Pairs, and in Combination

Individual Agents Alone ¹			MIC (μg/ml) for Identified Bacteria				
A	B	C	AV	FN	PG	SM	SS
RC1	--	--	15.6	62.5	7.8	15.6	15.6
--	BX1	--	62.5	62.5	15.6	62.5	62.5
--	--	CIT1	125	125	125	125	125
Pairings of Agents A, B & C ²							
RC1			15.6	31.3	3.9	7.8	15.6
+BX1			15.6	31.3	3.9	7.8	15.6
RC1			31.3	15.6	7.8	15.6	15.6
+CIT1			62.5	31.3	15.6	31.3	31.3
BX1			31.3	15.6	7.8	15.6	31.3
+CIT1			62.5	31.3	15.6	31.3	62.5
Triplets of Agents A, B & C ³							
RC1			7.8	15.6	3.9	7.8	7.8
+BX1			2.0	3.9	1.0	2.0	3.9
+CIT1			3.9	7.8	2.0	3.9	7.8
BX1			31.3	15.6	3.9	15.6	31.3
+RC1			7.8	3.9	2.0	3.9	1.0
+CIT1			15.6	7.8	3.9	7.8	2.0
CIT1			62.5	62.5	31.3	62.5	31.3
+RC1			3.9	3.9	1.0	1.0	3.9
BX1			3.9	3.9	1.0	1.0	3.9

Table 25
MIC of Berberine Hydrochloride, Hinokitiol and Geraniol
Alone, in Pairs, and in Combination

Individual Agents Alone ¹			MIC (μ g/ml) for Identified Bacteria				
A	B	C	AV	FN	PG	SM	SS
BX1	--	--	62.5	62.5	15.6	62.5	62.5
--	HK1	--	0.8	3.1	1.6	0.8	0.8
--	--	GRA1	125	125	125	125	250
Pairings of Agents A, B & C ²							
BX1			15.6	15.6	7.8	15.6	15.6
+HK1			0.8	0.8	0.4	0.8	0.8
BX1			31.3	31.3	7.8	62.5	31.3
+GRA1			62.5	62.5	15.6	62.5	62.5
HK1			0.8	1.6	0.8	0.8	0.8
+GRA1			31.3	62.5	31.3	31.3	31.3
Triplets of Agents A, B & C ³							
BX1			31.3	15.6	7.8	31.3	31.3
+HK1			0.2	0.4	0.05	0.05	0.2
+GRA1			7.8	15.6	2	2	7.8
HK1			0.4	0.8	0.4	0.4	0.4
+BX1			15.6	7.8	2	15.6	7.8
+GRA1			31.3	15.6	3.9	31.3	15.6
GRA1			62.5	31.3	31.3	62.5	31.3
+BX1			7.8	2	1	7.8	3.9
+HK1			0.4	0.1	0.05	0.4	0.2

Table 26
MIC of Berberine Hydrochloride, Hinokitiol and Juicy Fruit Basil Oil
Alone, in Pairs, and in Combination

5

Individual Agents Alone ¹			MIC (μg/ml) for Identified Bacteria				
A	B	C	AV	FN	PG	SM	SS
BX1	--	--	62.5	62.5	15.6	62.5	62.5
--	HK1	--	0.8	3.1	1.6	0.8	1.6
--	--	JFB1	125	125	31.3	62.5	7.8
Pairings of Agents A, B & C ²							
BX1			15.6	31.3	15.6	15.6	15.6
+HK1			0.8	1.6	0.8	0.8	0.8
BX1			31.3	31.3	7.8	31.3	31.3
+JFB1			62.5	62.5	15.6	62.5	62.5
HK1			0.8	1.6	0.2	0.8	0.8
+JFB1			31.3	62.5	7.8	31.3	31.3
Triplets of Agents A, B & C ³							
BX1			31.3	15.6	3.9	31.3	31.3
+HK1			0.2	0.4	0.05	0.05	0.1
+JFB1			7.8	15.6	2	2	3.9
HK1			0.4	0.8	0.4	0.4	0.8
+BX1			15.6	7.8	2	7.8	3.9
+JFB1			31.3	15.6	3.9	15.6	7.8
JFB1			62.5	31.3	7.8	15.6	3.9
+BX1			1	7.8	3.9	7.8	2
+HK1			1	0.4	0.2	0.4	0.1

Table 27
MIC of Berberine Hydrochloride, Hinokitiol and Citral
Alone, in Pairs, and in Combination

Individual Agents Alone ¹			MIC (µg/ml) for Identified Bacteria				
A	B	C	AV	FN	PG	SM	SS
BX1	--	--	62.5	62.5	15.6	62.5	125
--	HK1	--	0.8	3.1	1.6	0.8	0.8
--	--	CIT1	125	125	31.3	250	125
Pairings of Agents A, B & C ²							
BX1			15.6	31.3	7.8	15.6	15.6
+HK1			0.8	1.6	0.2	0.8	0.8
BX1			31.3	31.3	7.8	31.3	31.3
+CIT1			62.5	62.5	15.6	62.5	62.5
HK1			0.8	1.6	0.4	0.8	0.8
+CIT1			31.3	62.5	15.6	31.3	31.3
Triplets of Agents A, B & C ³							
BX1			31.3	15.6	3.9	31.3	31.3
+HK1			0.2	0.4	0.1	0.05	0.2
+CIT1			7.8	15.6	3.9	2	7.8
HK1			0.4	0.8	0.4	0.4	0.4
+BX1			15.6	7.8	3.9	15.6	3.9
+CIT1			31.3	15.6	7.8	31.3	7.8
CIT1			62.5	31.3	7.8	125	62.5
+BX1			3.9	7.8	2	1	1
+HK1			0.2	0.4	0.05	0.05	0.05

-38-

Table 28
MIC of Hinokitiol, Geraniol and Citral
Alone, in Pairs, and in Combination

Individual Agents Alone ¹			MIC (μ g/ml) for Identified Bacteria				
A	B	C	AV	FN	PG	SM	SS
HK1	--	--	1.6	1.6	1.6	0.8	0.8
--	GRA1	--	125	62.5	62.5	125	125
--	--	CIT1	125	62.5	62.5	125	125
Pairings of Agents A, B & C ²							
HK1			0.8	0.8	1.6	0.8	0.8
+GRA1			31.3	31.3	31.3	31.3	31.3
HK1			0.8	0.8	1.6	0.8	0.8
+CIT1			31.3	31.3	31.3	31.3	31.3
GRA1			62.5	31.3	31.3	62.5	31.3
+CIT1			62.5	31.3	31.3	62.5	31.3
Triplets of Agents A, B & C ³							
HK1			0.4	0.4	0.4	0.4	0.4
+GRA1			15.6	15.6	7.8	31.3	15.6
+CIT1			15.6	15.6	7.8	31.3	15.6
GRA1			125	15.6	15.6	62.5	31.3
+HK1			0.05	0.4	0.4	0.4	0.2
+CIT1			2	15.6	7.8	15.6	7.8
CIT1			62.5	7.8	15.6	62.5	7.8
+HK1			0.4	0.4	0.4	0.4	0.4
+GRA1			15.6	15.6	7.8	15.6	15.6

Table 29
MIC of Cedarwood Oil, Geraniol and Juicy Fruit Basil Oil
Alone, in Pairs, and in Combination

Individual Agents Alone ¹			MIC (μ g/ml) for Identified Bacteria				
A	B	C	AV	FN	PG	SM	SS
RC1	--	--	31.3	31.3	7.8	31.3	31.3
--	GRA1	--	62.5	62.5	62.5	125	62.5
--	--	JFB1	125	62.5	15.6	125	62.5
Pairings of Agents A, B & C ²							
RC1			15.6	15.6	7.8	15.6	15.6
+GRA1			31.3	31.3	15.6	31.3	31.3
RC1			15.6	15.6	3.9	7.8	7.8
+JFB1			31.3	31.3	7.8	15.6	15.6
GRA1			31.3	31.3	15.6	62.5	31.3
+JFB1			31.3	31.3	15.6	62.5	31.3
Triplets of Agents A, B & C ³							
RC1			15.6	15.6	3.9	3.9	7.8
+GRA1			2	2	3.9	31.3	7.8
+JFB1			2	2	3.9	31.3	7.8
GRA1			15.6	31.3	15.6	31.3	15.6
+RC1			3.9	2	1	2	2
+JFB1			7.8	3.9	2	3.9	3.9
JFB1			62.5	15.6	7.8	62.5	15.6
+RC1			1	3.9	1	3.9	3.9
+GRA1			2	7.8	2	7.8	7.8

-40-

Table 30
MIC of Cedarwood Oil, Juicy Fruit Basil Oil and Citral
Alone, in Pairs, and in Combination

Individual Agents Alone ¹			MIC (µg/ml) for Identified Bacteria				
A	B	C	AV	FN	PG	SM	SS
RC1	--	--	31.3	31.3	7.8	31.3	31.3
--	JFB1	--	125	62.5	250	125	62.5
--	--	CIT1	125	62.5	250	125	62.5
Pairings of Agents A, B & C ²							
RC1			31.3	15.6	7.8	15.6	7.8
+JFB1			62.5	31.3	15.6	31.3	15.6
RC1			15.6	15.6	62.5	15.6	15.6
+CIT1			31.3	31.3	125	31.3	31.3
JFB1			31.3	31.3	15.6	62.5	31.3
+CIT1			31.3	31.3	15.6	62.5	31.3
Triplets of Agents A, B & C ³							
RC1			15.6	3.9	2	3.9	7.8
+JFB1			2	15.6	3.9	31.3	7.8
+CIT1			2	15.6	3.9	31.3	7.8
JFB1			62.5	7.8	7.8	62.5	3.9
+RC1			1	7.8	31.3	2	7.8
+CIT1			2	15.6	62.5	3.9	15.6
CIT1			62.5	31.3	62.5	62.5	15.6
+RC1			2	1	2	2	2
+JFB1			3.9	2	3.9	3.9	3.9

Table 31
MIC of Berberine Hydrochloride, Juicy Fruit Basil Oil and Citral
Alone, in Pairs, and in Combination

Individual Agents Alone ¹			MIC (µg/ml) for Identified Bacteria				
A	B	C	AV	FN	CR	SM	SS
BX1	--	--	31.3	31.3	125	31.3	31.3
--	JFB1	--	62.5	125	250	62.5	62.5
--	--	CIT1	125	62.5	31.3	125	125
Pairings of Agents A, B & C ²							
BX1			31.3	15.6	3.9	31.3	31.3
+JFB1			62.5	31.3	7.8	62.5	62.5
BX1			31.3	15.6	62.5	31.3	15.6
+CIT1			62.5	31.3	125	62.5	31.3
JFB1			31.3	31.3	125	31.3	31.3
+CIT1			31.3	31.3	125	31.3	31.3
Triplets of Agents A, B & C ³							
BX1			7.8	3.9	62.5	7.8	7.8
+JFB1			15.6	15.6	3.9	15.6	7.8
+CIT1			15.6	15.6	3.9	15.6	7.8
JFB1			15.6	31.3	15.6	15.6	15.6
+BX1			7.8	3.9	31.3	7.8	3.9
+CIT1			15.6	7.8	62.5	15.6	7.8
CIT1			15.6	31.3	7.8	15.6	31.3
+BX1			15.6	1	1	15.6	7.8
+JFB1			31.3	2	2	31.3	15.6

-42-

Table 32
MIC of Berberine Hydrochloride, Juicy Fruit Basil Oil and Geraniol
Alone, in Pairs, and in Combination

Individual Agents Alone ¹			MIC (μg/ml) for Identified Bacteria				
A	B	C	AV	FN	CR	SM	SS
BX1	--	--	62.5	62.5	125	62.5	62.5
--	JFB1	--	125	125	250	125	125
--	--	GRA1	125	125	250	125	250
Pairings of Agents A, B & C ²							
BX1			31.3	15.6	62.5	31.3	31.3
+JFB1			62.5	31.3	125	62.5	62.5
BX1			31.3	15.6	62.5	31.3	31.3
+GRA1			62.5	31.3	125	62.5	62.5
JFB1			62.5	31.3	125	62.5	62.5
+GRA1			62.5	31.3	125	62.5	62.5
Triplets of Agents A, B & C ³							
BX1			15.6	15.6	62.5	15.6	15.6
+JFB1			15.6	2	2	15.6	15.6
+GRA1			15.6	2	2	15.6	15.6
JFB1			31.3	31.3	31.3	31.3	31.3
+BX1			7.8	2	31.3	7.8	7.8
+GRA1			15.6	3.9	62.5	15.6	15.6
GRA1			31.3	31.3	31.3	31.3	31.3
+BX1			7.8	1	15.6	7.8	7.8
+JFB1			15.6	2	31.3	15.6	15.6

-43-

Table 33
MIC of Berberine Hydrochloride, Citral and Geraniol
Alone, in Pairs, and in Combination

Individual Agents Alone ¹			MIC (μ g/ml) for Identified Bacteria				
A	B	C	AV	FN	CR	SM	SS
BX1	--	--	62.5	62.5	125	62.5	62.5
--	CIT1	--	125	125	250	125	125
--	--	GRA1	250	125	250	125	125
Pairings of Agents A, B & C ²							
BX1			31.3	31.3	62.5	31.3	15.6
+CIT1			62.5	62.5	125	62.5	31.3
BX1			31.3	15.6	62.5	15.6	15.6
+GRA1			62.5	31.3	125	31.3	31.3
CIT1			62.5	62.5	125	62.5	31.3
+GRA1			62.5	62.5	125	62.5	31.3
Triplets of Agents A, B & C ³							
BX1			31.3	15.6	31.3	15.6	15.6
+CIT1			15.6	7.8	31.3	15.6	7.8
+GRA1			15.6	7.8	31.3	15.6	7.8
CIT1			62.5	62.5	7.8	62.5	15.6
+BX1			15.6	2	31.3	1	3.9
+GRA1			31.3	3.9	62.5	2	7.8
GRA1			62.5	31.3	62.5	62.5	31.3
+BX1			7.8	2	7.8	7.8	1
+CIT1			15.6	3.9	15.6	15.6	2

Table 34
MIC of Hinokitiol, Juicy Fruit Basil Oil and Citral
Alone, in Pairs, and in Combination

Individual Agents Alone ¹			MIC (µg/ml) for Identified Bacteria				
A	B	C	AV	FN	CR	SM	SS
HK1	--	--	0.8	3.1	3.2	0.8	0.8
--	JFB1	--	250	125	500	125	125
--	--	CIT1	125	125	500	125	125
Pairings of Agents A, B & C ²							
HK1			0.8	1.6	3.2	0.8	0.8
+JFB1			31.3	62.5	125	31.3	31.3
HK1			0.8	0.8	3.2	0.8	0.8
+CIT1			31.3	31.3	125	31.3	31.3
JFB1			31.3	31.3	125	31.3	62.5
+CIT1			31.3	31.3	125	31.3	62.5
Triplets of Agents A, B & C ³							
HK1			0.4	1.6	1.6	0.4	0.4
+JFB1			15.6	2	15.6	15.6	15.6
+CIT1			15.6	2	15.6	15.6	15.6
JFB1			62.5	31.3	3.9	62.5	31.3
+HK1			0.4	0.4	1.6	0.1	0.2
+CIT1			7.8	15.6	62.5	3.9	7.8
CIT1			31.3	31.3	7.8	62.5	31.3
+HK1			0.2	0.4	1.6	0.05	0.2
+JFB1			7.8	15.6	62.5	2	7.8

Table 35
MIC of Hinokitiol, Juicy Fruit Basil Oil and Geraniol
Alone, in Pairs, and in Combination

Individual Agents Alone ¹			MIC (µg/ml) for Identified Bacteria				
A	B	C	AV	FN	CR	SM	SS
HK1	--	--	0.8	3.1	3.1	0.8	0.8
--	JFB1	--	125	125	250	125	125
--	--	GRA1	125	125	250	125	125
Pairings of Agents A, B & C ²							
HK1			0.8	1.6	3.1	0.8	0.8
+JFB1			31.3	62.5	125	31.3	31.3
HK1			0.8	1.6	0.8	1.6	0.8
+GRA1			31.3	62.5	62.5	31.3	31.3
JFB1			31.3	31.3	125	62.5	62.5
+GRA1			31.3	31.3	125	62.5	62.5
Triplets of Agents A, B & C ³							
HK1			0.4	1.6	1.6	0.1	0.4
+JFB1			7.8	7.8	3.9	31.3	15.6
+GRA1			7.8	7.8	3.9	31.3	15.6
JFB1			31.3	31.3	62.5	62.5	62.5
+HK1			0.2	0.4	0.8	0.1	0.05
+GRA1			7.8	15.6	31.3	3.9	2
GRA1			62.5	31.3	62.5	62.5	62.5
+JFB1			3.9	15.6	31.3	7.8	3.9
+HK1			0.1	0.4	0.8	0.2	0.1

This example illustrates how the MIC of antimicrobial agents A, B and C in combination is reduced relative to the MIC of the individual antimicrobial agents in the absence of the other antimicrobial agents.

Example 3

5

Dentifrice formulations

The following example describes dentifrices comprising combinations of antimicrobial agents A, B, and C formed in accordance with the present invention.

Table 36

Formulation 18-12: 0.2% Cedarwood Oil, 0.1% Juicy Fruit Basil Oil,
10 0.02% Citral (W/W)

Component	Wt. %
Sorbitol 70% in water	39.72
Poloxamer 407 (PLURONIC® F127)	5.0
deionized water	25.901
Carbomer 940 (CARBOPOL® 940)	0.3
sodium hydroxide	0.205
xanthan gum	0.40
glycerin	2.5
sodium fluoride	0.254
sodium saccharine	0.400
SYLODENT® 750 (silica)	10.0
SYLODENT® 15 (silica)	12.0
flavoring agent	1.0
titanium dioxide	0.50
sodium lauryl sulfate	1.5
cedarwood oil	0.200
juicy fruit basil oil	0.100
citral	0.020

Table 37
Formulation 18-36: 0.4% Cedarwood Oil, 0.01% Berberine Hydrochloride (W/W)

Component	Wt. %
Sorbitol 70% in water	40.050
Poloxamer 407 (PLURONIC® F127)	5.0
deionized water	25.386
Carbomer 940 (CARBOPOL® 940)	0.3
sodium hydroxide	0.2
xanthan gum	0.4
glycerin	5.0
sodium fluoride	0.254
sodium saccharine	0.800
SYLODENT® 750 (silica)	10.0
SYLODENT® 15 (silica)	10.0
cedarwood oil	0.40
berberine hydrochloride hydrate	0.01
flavoring agent	1.00
FD&C Blue #1, 1% solution	0.2
sodium lauryl sulfate	1.00

5

Table 38
Formulation 18-55: 0.4% Cedarwood Oil, 0.1%
 Geraniol, and 0.01% Berberine Hydrochloride (W/W)

Component	Wt. %
Sorbitol 70%	40.05
deionized water	24.486
berberine hydrochloride hydrate	0.01
Carbomer 940 (CARBOPOL® 940)	0.30
Poloxamer 407 (PLURONIC® F127)	5.00
sodium hydroxide	0.20
xanthan gum	0.40

Component	Wt. %
sodium fluoride	0.254
sodium saccharine	0.80
SYLODENT® 750 (silica)	10.0
SYLODENT® 15 (silica)	10.0
flavoring agent	1.0
titanium dioxide	1.0
sodium lauryl sulfate	1.0
glycerin	5.0
cedarwood oil	0.4
geraniol	0.10

Table 39

Formulation 18-37: 0.4% Cedarwood Oil, 0.1% Geraniol, and 0.05% Citral (W/W)

Component	Wt. %
Sorbitol 70% in water	40.050
Poloxamer 407 (PLURONIC® F127)	5.0
deionized water	25.246
Carbomer 940 (CARBOPOL® 940)	0.3
sodium hydroxide	0.2
xanthan gum	0.4
glycerin	5.0
sodium fluoride	0.254
sodium saccharine	0.800
SYLODENT® 750 (silica)	10.0
SYLODENT® 15 (silica)	10.0
cedarwood oil	0.40
geraniol	0.10
citral	0.050
flavoring agent	1.00
FD&C Blue #1, 1% solution	0.2
sodium lauryl sulfate	1.00

5 Carbomer refers to polymer composed of acrylic acid cross-linked with allyl sucrose available as CARBOPOL® 940. CARBOPOL® 940 is commercially available from B.F. Goodrich. SYLODENT® 750 is a silica gel (silicon dioxide) and SYLODENT® 15 is a silica gel (silicon dioxide). SYLODENT® is available commercially from W.R. Grace & Co. - Conn. Davison Chemical Division.

Table 40

Formulation 18-58: 0.4% Cedarwood Oil, 0.1% Geraniol (W/W)

Component	Wt. %
Sorbitol 70%	40.05
deionized water	25.286
berberine hydrochloride hydrate	0.01
Carbomer 940 (CARBOPOL® 940)	0.3
Poloxamer 407 (PLURONIC® F127)	5.0
sodium hydroxide	0.2
xanthan gum	0.4
sodium fluoride	0.254
sodium saccharine	0.8
SYLODENT® 750 (silica)	10.0
SYLODENT® 15 (silica)	10.0
flavoring agent	1.0
FD&C Blue #1, 1% solution	0.2
sodium lauryl sulfate	1.0
glycerin	5.0
cedarwood oil	0.4
geraniol	0.1

10 Poloxamer 407 is available under the trademark PLURONIC® F127 from BASF Corporation. PLURONIC® F127 is a nonionic difunctional block polymer terminating in primary hydroxyl groups with molecular weights ranging from 1,000 to about 15,000. They include polyoxyalkylene derivatives of propylene glycol.

15 The formulations described above were formed in a vacuum mixer by adding the deionized water and dispersing the Carbomer while pulling a vacuum. When the

Carbomer was well dispersed, the sodium hydroxide was added. In another vessel, the 70% sorbitol solution and Poloxamer was heated and mixed. The Poloxamer solution was then added to the vacuum mixture and blended with the Carbomer mixture. Xanthan gum was then added to the glycerin, and the resulting solution was 5 added to the vacuum mixer and incorporated into the mixture. The salts were then added to the vacuum mixer, followed by silicas which were slowly mixed in. Active agents, flavor, sodium lauryl sulfate and coloring agents were then added and allowed to mix until well incorporated.

Example 4

10

Customer Acceptance

This example illustrates customer acceptance of dentifrice formulations incorporating combinations of antimicrobial agents A, B, and optionally C formed in accordance with the present invention.

15 The formulations set forth above in Tables 36-40 were evaluated for customer acceptance. Formulation 5-99 was a dentifrice available commercially as Listerine® Cool Mint gel.

20 The preference study was carried out with a group of approximately 20 people. One tube of dentifrice formulation was given to each person to use over the course of a week. At the end of the week, participants filled out a questionnaire, the results of which are summarized in Table 41 below. The scoring range was 1-10 with 1 being poor and 10 being good. The scores were tallied and averaged.

Table 41
Consumer Evaluation

Formulation	18-12	18-36	18-55	18-37	18-58	5-99
Color	6.61	6.52	3.20	7.13	7.17	7.25
Appearance	6.27	6.74	3.75	6.91	6.89	6.75
Taste	5.09	4.96	5.05	4.17	6.50	4.00
After Taste	5.22	5.13	5.20	4.48	6.50	3.85
Aroma	5.00	6.35	5.35	4.52	6.94	4.55
Cleaning	6.22	6.48	5.95	6.39	6.78	6.10
Foam	6.22	6.30	6.00	6.19	6.00	5.85
Consistency	6.09	6.39	6.25	6.04	5.67	5.75

Formulation	18-12	18-36	18-55	18-37	18-58	5-99
Dry Mouth	6.09	6.26	7.05	6.78	7.94	5.70
Next Morning Feel	5.43	5.87	5.50	5.28	6.33	5.15
Overall Mouth Feel	5.61	5.78	5.80	5.57	6.61	4.45
Overall Satisfaction	5.04	5.37	5.20	5.53	6.44	4.20

This example illustrates that the overall consumer satisfaction for formulations with antimicrobial agents in accordance with the present invention is greater than the overall consumer satisfaction for the commercially available product, Listerine® Cool Mint gel.

5

Example 5

Ethanol Extraction of *Glycyrrhiza glabra*

25 grams of powdered plant material from *Glycyrrhiza glabra* was combined with 250 grams of a 95:5 ethanol/water mixture. The mixture was stirred overnight at room temperature. Solids were removed from the stirred mixture with a No. 4 10 Whatman filter in a Buchner funnel. Further removal of solids was achieved with a No. 5 Whatman filter in a Buchner funnel. Additional solids were removed with a Whatman 1 micrometer filter in a Buchner funnel. A vacuum filtration apparatus and a 0.2 micrometer filter was employed to clean the solution a final time. The clean solution was then concentrated down to a solid using a rotovaporizer. 15 Approximately, 2.5 grams of a rust colored solid was collected as the crude extract of *Glycyrrhiza glabra*.

While the preferred embodiment of the invention has been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention.

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A therapeutic composition for inhibiting the growth of bacteria comprising:

antimicrobial agent A and antimicrobial agent B in amounts effective to inhibit the growth of bacteria, agents A and B selected from the group consisting of berberine, cedarwood oil, chloramphenicol, citral, citronella oil, cocamidopropyl dimethylglycine, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, juniper berries oil, lemon basil oil, lemon oil, and *Rosmarinus officinalis* oil.

2. The composition of Claim 1, wherein the minimum inhibitory concentration for agent A in the presence of agent B is less than the minimum inhibitory concentration of agent A alone.

3. The composition of Claim 2, wherein the minimum inhibitory concentration for agent B in the presence of agent A is less than the minimum inhibitory concentration of agent B alone.

4. The composition of Claim 3, wherein the bacteria are oral pathogenic bacteria selected from the group consisting of *Actinomyces viscosus*, *Fusobacterium nucleatum*, *Porphyromonas gingivalis*, *Streptococcus mutans*, and *Streptococcus sanguis*.

5. The composition of Claim 1, wherein agent A is cedarwood oil.

6. The composition of Claim 5, wherein agent B is selected from the group consisting of berberine, chloramphenicol, citral, cocamidopropyl dimethylglycine, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, and *Rosmarinus officinalis* oil.

7. The composition of Claim 6, wherein agent B is selected from the group consisting of berberine, chloramphenicol, citral, cocamidopropyl dimethylglycine, and *Glycyrrhiza glabra* extract.

8. The composition of Claim 1, wherein agent A is berberine.

9. The composition of Claim 8, wherein agent B is selected from the group consisting of chloramphenicol, citral, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, juniper berries oil, and lemon basil oil.

10. The composition of Claim 9, wherein agent B is selected from the group consisting of chloramphenicol, *Glycyrrhiza glabra* extract, and lemon basil oil.

11. The composition of Claim 1, wherein agent A is hinokitiol.

12. The composition of Claim 11, wherein agent B is selected from the group consisting of chloramphenicol, citral, cocamidopropyl dimethylglycine, *Glycyrrhiza glabra* extract, juniper berries oil, and lemon basil oil.

13. The composition of Claim 12, wherein agent B is selected from the group consisting of chloramphenicol, cocamidopropyl dimethylglycine, and *Glycyrrhiza glabra* extract.

14. The composition of Claim 1, wherein agent A is *Glycyrrhiza glabra* extract.

15. The composition of Claim 14, wherein agent B is selected from the group consisting of chloramphenicol, cocamidopropyl dimethylglycine, juicy fruit basil oil, and lemon basil oil.

16. The composition of Claim 15, wherein agent B is selected from the group consisting of chloramphenicol and cocamidopropyl dimethylglycine.

17. The composition of Claim 1, further comprising an antimicrobial agent C different from antimicrobial agent A and antimicrobial agent B, agent C being present in an amount effective to inhibit the growth of bacteria and selected from the group consisting of berberine, cedarwood oil, chloramphenicol, citral, citronella oil, cocamidopropyl dimethylglycine, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, juniper berries oil, lemon basil oil, lemon oil, and *Rosmarinus officinalis* oil.

18. A composition for inhibiting the growth of bacteria comprising: an antimicrobial agent A comprising geraniol; and

an antimicrobial agent B selected from the group consisting of *berberine*, cedarwood oil, chloramphenicol, citral, citronella oil, cocamidopropyl dimethylglycine, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, juniper berries oil, lemon basil oil, lemon oil, and *Rosmarinus officinalis* oil.

19. The composition of Claim 18, further comprising an antimicrobial agent C different from antimicrobial agent A and antimicrobial agent B selected from the group consisting of berberine, cedarwood oil, chloramphenicol, citral, citronella oil, cocamidopropyl dimethylglycine, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, juniper berries oil, lemon basil oil, lemon oil, and *Rosmarinus officinalis* oil.

20. An oral hygiene product comprising the composition of Claim 18.

21. A method of inhibiting the growth of bacteria on a surface comprising the steps of contacting the surface with the composition of Claim 18.

22. An oral hygiene product comprising:

antimicrobial agent A and antimicrobial agent B in amounts effective to inhibit the growth of bacteria wherein agents A and B are selected from the group consisting of berberine, cedarwood oil, chloramphenicol, citral, citronella oil, cocamidopropyl dimethylglycine, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, juniper berries oil, lemon basil oil, lemon oil, and *Rosmarinus officinalis* oil.

23. The oral hygiene product of Claim 22, wherein the minimum inhibitory concentration for agent A in the presence of agent B is less than the minimum inhibitory concentration of agent A alone.

24. The oral hygiene product of Claim 23, wherein the minimum inhibitory concentration for agent B in the presence of agent A is less than the minimum inhibitory concentration of agent B alone.

25. The oral hygiene product of Claim 24, wherein the bacteria are oral pathogenic bacteria selected from the group consisting of *Actinomyces viscosus*, *Fusobacterium nucleatum*, *Porphyromonas gingivalis*, *Streptococcus mutans*, and *Streptococcus sanguis*.

26. The oral hygiene product of Claim 22, wherein agent A is selected from the group consisting of cedarwood oil, berberine, hinokitiol and *Glycyrrhiza glabra* extract.

27. The oral hygiene product of Claim 22, further comprising antimicrobial agent C, different from agent A and agent B, agent C being present in an amount effective to inhibit the growth of bacteria and selected from the group consisting of berberine, cedarwood oil, chloramphenicol, citral, citronella oil, cocamidopropyl dimethylglycine, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, juniper berries oil, lemon basil oil, lemon oil, and *Rosmarinus officinalis* oil.

28. A method for inhibiting the growth of bacteria on a surface comprising the step:

contacting the surface with a composition that includes antimicrobial agent A and antimicrobial agent B in an amount effective to inhibit the growth of bacteria, agents A and B selected from the group consisting of berberine, cedarwood oil, chloramphenicol, citral, citronella oil, cocamidopropyl dimethylglycine, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, juniper berries oil, lemon basil oil, lemon oil, and *Rosmarinus officinalis* oil.

29. The method of Claim 28, wherein the minimum inhibitory concentration of agent A in the presence of agent B is less than the minimum inhibitory concentration of agent A alone.

30. The method of Claim 29, wherein the minimum inhibitory concentration for agent B in the presence of agent A is less than the minimum inhibitory concentration of agent B alone.

31. The method of Claim 30, wherein the bacteria are oral pathogenic bacteria selected from the group consisting of *Actinomyces viscosus*, *Fusobacterium nucleatum*, *Porphyromonas gingivalis*, *Streptococcus mutans*, and *Streptococcus sanguis*.

32. The method of Claim 28, wherein the antimicrobial agent A is selected from the group consisting of cedarwood oil, berberine, hinokitiol and *Glycyrrhiza glabra* extract.


33. The method of Claim 28, wherein the composition that includes antimicrobial agents A and B further comprises an antimicrobial agent C different from agent A and agent B, agent C being present in an amount effective to inhibit the growth of bacteria and selected from the group consisting of berberine, cedarwood oil, chloramphenicol, citral, citronella oil, cocamidopropyl dimethylglycine, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, juniper berries oil, lemon basil oil, lemon oil, and *Rosmarinus officinalis* oil.

34. A method of reducing the minimum inhibitory concentration of an antimicrobial agent A selected from the group consisting of berberine, cedarwood oil, chloramphenicol, citral, citronella oil, cocamidopropyl dimethylglycine, geraniol, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, juniper berries oil, lemon basil oil, lemon oil, and *Rosmarinus officinalis* oil, comprising:

combining agent A with an antimicrobial agent B different from agent A selected from the group consisting of berberine, cedarwood oil, chloramphenicol, citral, citronella oil, cocamidopropyl dimethylglycine, geraniol, *Glycyrrhiza glabra* extract, hinokitiol, juicy fruit basil oil, juniper berries oil, lemon basil oil, lemon oil, and *Rosmarinus officinalis* oil, the minimum inhibitory concentration of agent A in the presence of agent B being less than the minimum inhibitory concentration of agent A alone.

35. The method of Claim 34, wherein the step of combining agent B with agent A results in a synergistic reduction in the minimum inhibitory concentration of agent A.

1/1



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/06468

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/47 A61K31/165 A61K31/11 A61K31/12 A61K35/78
A61K7/26 A61K7/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE "CHEMICAL ABSTRACTS" (HOST: STN); Abs. 123:3404, Columbus, OH, USA; & JP 07 089 819 A (JUMOKU CHUSHUTSU SEIBUN RYO) 4 APRIL 1995 XP002071508 see the whole document ---	1,5,6, 11,21, 28-35
X	DATABASE "CHEMICAL ABSTRACTS" (HOST: STN); Abs. 102: 31949, Columbus, OH, USA; & JP 59 175 410 A (KANEBO FOODS, Ltd) 4 OCTOBER 1984 XP002071509 see the whole document ---	1,4, 17-35

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

^o Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

16 July 1998

Date of mailing of the international search report

29/07/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Glikman, J-F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/06468

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE "CHEMICAL ABSTRACTS" (HOST: STN); Abs. 121: 53 735, Columbus, OH, USA; & M. YOKOTA et al.: "Antimicrobial effect of aromatic natural compound, chiefly XP002071510 against <i>Staphylococcus aureus</i> " IGAKU TO SEIBUTSUGAKU (1994), 128(3), pp 105-110 see the whole document ---	1, 11, 12, 18, 19, 21, 28-35
X	DATABASE "CHEMICAL ABSTRACTS" (HOST: STN); Abs. :75 133 025, Columbus, OH, USA; & JP 46 028 430 B4 (OTSUKA PHARM. CO.,Ltd) 18 AUGUST 1971 XP002071511 see the whole document ---	1, 14-17, 21-35
X	DATABASE "CHEMICAL ABSTRACTS" (HOST: STN); Abs. 99 181 502, Columbus, OH, USA; & JP 58 140 014 A (S.S. PHARMACEUTICAL CO. Ltd) 19 AUGUST 1983 XP002071512 see the whole document ---	1, 8-10, 14, 28-35
A	DATABASE "CHEMICAL ABSTRACTS" (HOST: STN); Abs.101: 59 975, Columbus, OH, USA; & M. ADAMES et al.: " Study of the essential oil of <i>Eucalyptus citriodora</i> XP002071513 Bailey" REV. COLOMB. CIENC. QUIM.-FARM. (1983),4(1),95-113 see the whole document ---	1, 18, 19, 21, 28-35
X	DATABASE "CHEMICAL ABSTRACTS" (HOST: STN) Abs. 121: 263 407, Columbus, OH, USA; & B. KEDZIA et al.: "Composition and anti- microbial characteristics of <i>Melissa</i> oil XP002071514 and its components" HERBA POL., 1994, 40(1-2),5-11 see the whole document ---	1-4, 18, 19, 21, 28-35
X	FR 2 377 195 A (M. THENOUX) 11 August 1978 see the whole document ---	1, 28-35
X	GB 1 214 914 A (AIRWICK INDUSTRIES, INC.) 9 December 1970 see example 2 ---	1, 5
4 P, X	EP 0 805 198 A (THE PROCTER & GAMBLE CO.) 5 November 1997 see page 5, line 1-34; claims 1,8 ---	1 -/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/06468

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	FR 2 743 722 A (M. PUYRAVAUD) 25 July 1997 see the example see claims 2,3 ---	1
A	US 4 145 412 A (P. LADANYI) 20 March 1979 ---	1,8,22
X	S. MEGALLA ET AL.: "a study of antimicrobial action of some essential oil constituents" HERBA POL., vol. 26, no. 3, 1980, pages 181-186, XP002071506 see table 5 ---	1-4
A	J. MORRIS ET AL.: "Antimicrobial activity of aroma chemicals and essential oils" J. AM. OIL CHEM. SOC., vol. 56, no. 5, 1979, pages 595-603, XP000645444 -----	1-4

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/06468

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
FR 2377195	A 11-08-1978	NONE		
GB 1214914	A 09-12-1970	AT 290683 B		15-05-1971
		CH 480923 A		15-11-1969
		DE 1553657 A		27-05-1971
		FR 1564219 A		18-04-1969
		JP 48024290 B		20-07-1973
		US 3568026 A		02-03-1971
EP 805198	A 05-11-1997	AU 2925797 A		26-11-1997
		WO 9742280 A		13-11-1997
FR 2743722	A 25-07-1997	NONE		
US 4145412	A 20-03-1979	BE 874607 A		02-07-1979
		CH 638973 A		31-10-1983
		DE 2907406 A		04-09-1980
		FR 2450605 A		03-10-1980
		GB 2042336 A, B		24-09-1980
		JP 1010490 B		22-02-1989
		JP 1531780 C		24-11-1989
		JP 55111413 A		28-08-1980
		NL 7901496 A, B,		28-08-1980